Protalix Biotherapeutics Inc

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins using its ProCellEx plant cell-based protein expression system. It provides Elelyso for Gaucher disease and Elfabrio for adult patients with confirmed Fabry disease. The company is also developing PRX-115, a plant cell-expressed PEGylated uricase in Phase 2 trials for gout, and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I candidate for neutrophil extracellular traps diseases. It has agreements with Pfizer, Fundação Oswaldo Cruz, and Chiesi Farmaceutici S.p.A., and a strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack, New Jersey.

PLX▲

Protalix Q2 2026 revenue rises on Elfabrio growth

Protalix BioTherapeutics reported second quarter 2026 total revenues of $19.9 million, up from $15.7 million a year earlier, driven by higher sales of Elfabrio through its partner Chiesi. Net income for the quarter was $3.8 million, or $0.05 per share, compared with $164,000, or $0 per share, in the second quarter of 2025. The company reiterated its full year 2026 revenue guidance and said it expects top-line results from the RELEASE study of PRX-115 in uncontrolled gout in the second half of 2027. Cash, cash equivalents and short-term bank deposits totaled $40.7 million as of June 30, 2026, with no outstanding debt or warrants.

PLX ▲

The Motley Fool·30dRead more →